These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 34032930)
1. Challenges in hepatitis C elimination despite highly effective antiviral agents in patients with and without intravenous drug use. Bota S; Razpotnik M; Hucke F; Urak C; Flatscher K; Peck-Radosavljevic M Wien Klin Wochenschr; 2021 Jul; 133(13-14):641-646. PubMed ID: 34032930 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis. Graf C; Mücke MM; Dultz G; Peiffer KH; Kubesch A; Ingiliz P; Zeuzem S; Herrmann E; Vermehren J Clin Infect Dis; 2020 May; 70(11):2355-2365. PubMed ID: 31513710 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users. Hsu JT; Hsu PI; Shie CB; Chuah SK; Wu IT; Huang WW; Tang SY; Tsai KF; Kuo LF; Ghose S; Hsu JC; Shih CA Medicina (Kaunas); 2022 Mar; 58(3):. PubMed ID: 35334612 [TBL] [Abstract][Full Text] [Related]
4. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy. Akiyama MJ; Lipsey D; Heo M; Agyemang L; Norton BL; Hidalgo J; Lora K; Litwin AH Clin Infect Dis; 2020 Jun; 70(12):2695-2702. PubMed ID: 31346609 [TBL] [Abstract][Full Text] [Related]
5. Belgian experience with direct acting antivirals in people who inject drugs. Bielen R; Moreno C; Van Vlierberghe H; Bourgeois S; Mulkay JP; Vanwolleghem T; Verlinden W; Brixko C; Decaestecker J; De Galocsy C; Janssens F; Cool M; Van Overbeke L; Van Steenkiste C; D'heygere F; Cools W; Nevens F; Robaeys G Drug Alcohol Depend; 2017 Aug; 177():214-220. PubMed ID: 28618285 [TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort. Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ; J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429 [TBL] [Abstract][Full Text] [Related]
7. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data. Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446 [TBL] [Abstract][Full Text] [Related]
8. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387 [TBL] [Abstract][Full Text] [Related]
9. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada. Selfridge M; Cunningham EB; Barnett T; Drost A; Gray-Schleihauf C; Guarasci K; Lundgren K; Milne R; Grebely J; Fraser C Int J Drug Policy; 2021 Oct; 96():103418. PubMed ID: 34538704 [TBL] [Abstract][Full Text] [Related]
10. Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study. Heo M; Norton BL; Pericot-Valverde I; Mehta SH; Tsui JI; Taylor LE; Lum PJ; Feinberg J; Kim AY; Arnsten JH; Sprecht-Walsh S; Page K; Murray-Krezan C; Anderson J; Litwin AH; J Hepatol; 2024 May; 80(5):702-713. PubMed ID: 38242324 [TBL] [Abstract][Full Text] [Related]
11. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy. Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585 [TBL] [Abstract][Full Text] [Related]
12. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA; J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642 [TBL] [Abstract][Full Text] [Related]
13. Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland. Caven M; Baiano CX; Robinson EM; Stephens B; Macpherson I; Dillon JF J Viral Hepat; 2021 Dec; 28(12):1744-1750. PubMed ID: 34525228 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis. Muller A; Vlahov D; Akiyama MJ; Kurth A Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32659974 [TBL] [Abstract][Full Text] [Related]
15. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial. Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528 [TBL] [Abstract][Full Text] [Related]
16. Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. Cunningham EB; Hajarizadeh B; Amin J; Hellard M; Bruneau J; Feld JJ; Cooper C; Powis J; Litwin AH; Marks P; Dalgard O; Conway B; Moriggia A; Stedman C; Read P; Bruggmann P; Lacombe K; Dunlop A; Applegate TL; Matthews GV; Fraser C; Dore GJ; Grebely J Clin Infect Dis; 2021 Apr; 72(8):1392-1400. PubMed ID: 32166305 [TBL] [Abstract][Full Text] [Related]
17. Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs. Latham NH; Doyle JS; Palmer AY; Vanhommerig JW; Agius P; Goutzamanis S; Li Z; Pedrana A; Gottfredsson M; Bouscaillou J; Luhmann N; Mazhnaya A; Altice FL; Saeed S; Klein M; Falade-Nwulia OO; Aspinall E; Hutchinson S; Hellard ME; Sacks-Davis R Liver Int; 2019 Dec; 39(12):2244-2260. PubMed ID: 31125496 [TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh. Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689 [TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus micro-elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide. Tai CM; Yu ML Kaohsiung J Med Sci; 2024 Feb; 40(2):112-118. PubMed ID: 38010851 [TBL] [Abstract][Full Text] [Related]
20. Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C). Rapoud D; Quillet C; Pham Minh K; Vu Hai V; Nguyen Thanh B; Nham Thi Tuyet T; Tran Thi H; Molès JP; Vallo R; Michel L; Feelemyer J; Weiss L; Lemoine M; Vickerman P; Fraser H; Duong Thi H; Khuat Thi Hai O; Des Jarlais D; Nagot N; Laureillard D; BMJ Open; 2020 Nov; 10(11):e039234. PubMed ID: 33208326 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]